SignalSilence ® Met siRNA I from Cell Signaling Technology

Product Specs
ItemSignalSilence ® Met siRNA I
CompanyCell Signaling Technology
Price $369.00 Inquire
Catalog Number6618S
Quantity300 µl
TargetMet
NCBI Gene AliasesAUTS9, DA11, DFNB97, HGFR, RCCP2, c-Met
NCBI Full Gene NameMET proto-oncogene, receptor tyrosine kinase
Research AreaRTK
ReactivityH
ApplicationssiRNA
TypesiRNA

Add to Compare List

Cell Signaling Technology

3 Trask Lane

Danvers, Massachusetts 01923

United States

Phone: 877-616-CELL
Phone: 978-867-2388
Fax: 866-432-6112
Fax: 978-867-2488

Company Profile

Website: http://www.cellsignal.com/

Website: Technical Support

(1) Effects of Otago Exercise Program on postural control ability in elders living in the nursing home: A systematic review and meta-analysisMedicine (Baltimore)March 17, 2023Lingyu Kong, Xinwen Zhang, Xinrui Zhu, Lingyue Meng, Qiuxia Zhangwas performed in BBS (t = −1.67, P = .2374), TUG (t = 1.25, P = .3008), and 30s-CST (t = −0.51, P = .6618), and was not performed for the number of studies being too small in terms of functional mobility in

(2) HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical FindingsInternational journal of molecular sciencesNovember 20, 2020Boschert V, Teusch J, Aljasem A, Schmucker P, Klenk N, Straub A, Bittrich M, Seher A, Linz C, Müller-Richter UDA, et al.reverse transfected with 10 pmol Met siRNA I, Met siRNA II, or control siRNA (Signal Silence siRNA 6568, 6618 or 6622, Cell Signaling, Denvers, CO, USA). Per sample, 3 µL Lipofectamine RNAiMAX reagent (ThermoFisher Scientific

(3) HER2-mediated enhancement of Ebola virus entryPLoS pathogensOctober 1, 2020Kuroda M, Halfmann P, Kawaoka Y.determined. Transfection of siRNA Human siRNAs for HER2 (4390824_s613 and 4392420_s612, Ambion), MET (6618 and 6622, Cell signaling technology), IR (AM51331_29 and AM51331_31, Ambion), IGF-1R (AM51331_110754

(4) PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non‑small cell lung cancerOncology LettersApril 26, 2018Chunan Bian, Zonghang Liu, Dakou Li, Lifeng Zhen(si-p110α; 100 nM; cat. no. 6359S), AKT (si-AKT; 100 nM; cat. no. 6211S) and MET (si-MET; 100 nM; cat. no. 6618S) were obtained from Cell Signaling Technology Inc. (Danvers, MA, USA). Transfection was performed using

(5) The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive BehaviorEBioMedicineJune 1, 2017Weinberg F, Reischmann N, Fauth L, Taromi S, Mastroianni J, Köhler M, Halbach S, Becker AC, Deng N, Schmitz T, et al.

(6) Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcomaBMC cancerMay 16, 2017Yamada S, Imura Y, Nakai T, Nakai S, Yasuda N, Kaneko K, Outani H, Takenaka S, Hamada K, Myoui A, et al.according to the manufacturer’s instruction. Two kinds of siRNAs targeting c-MET (constructs I and II; #6618 and #6622) and a non-targeting siRNA (#6568) were purchased from Cell Signaling Technology, Inc. Two

(7) Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatmentCancer lettersOctober 1, 2016Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, et al.

(8) c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastomaThe Journal of clinical investigationMay 2, 2016Huang M, Liu T, Ma P, Mitteer RA Jr, Zhang Z, Kim HJ, Yeo E, Zhang D, Cai P, Li C, et al.control siRNA (QIAGEN, catalog 1027280) or siRNA targeting c-Met (Cell Signaling Technology, catalog 6618), MMP-2 (Invitrogen, catalog s8851), MMP-14 (Invitrogen, catalog s8877), NF-κB (Cell Signaling Technology,

(9) Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cellsNature communicationsFebruary 19, 2016Ramirez M, Rajaram S, Steininger RJ, Osipchuk D, Roth MA, Morinishi LS, Evans L, Ji W, Hsu CH, Thurley K, et al.Fig. 6d–g). Transient knockdown of MET was achieved using SignalSilence MET siRNA I (Cell Signaling #6618), with SignalSilence Control siRNA (Cell Signaling #6568) as a negative control. Cells were seeded in

(10) Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcomaMolecular cancerAugust 7, 2014Imura Y, Yasui H, Outani H, Wakamatsu T, Hamada K, Nakai T, Yamada S, Myoui A, Araki N, Ueda T, et al.Lipofectamine 2000 (Life Technologies). Two kinds of siRNAs targeting c-MET (constructs I and II; #6618 and #6622) and mTOR (construct I and II; #6381 and #6556), and a non-targeting siRNA (#6568) were purchased

(11) Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCSBMC cancerJune 19, 2014Outani H, Tanaka T, Wakamatsu T, Imura Y, Hamada K, Araki N, Itoh K, Yoshikawa H, Naka N.interfering RNAs (siRNAs). Two kinds of siRNAs against MET were purchased from Cell Signaling Technology (#6618S). In vivo models Phosphoreceptor tyrosine kinase (RTK) array To evaluate the expression of phosphorylated

Be the First to Write a Review!